Table Of Content:
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cancer Gene Therapy
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cancer Gene Therapy Market By Type
1.2.2.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Cancer Gene Therapy Market Revenue Share By Type in 2017
1.2.2.3. Ex-vivo
1.2.2.4. In-vivo
1.2.2.5. Others
1.2.3. Cancer Gene Therapy Market By Product
1.2.3.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.3.2. Global Cancer Gene Therapy Market Revenue Share By Product in 2017
1.2.3.3. Viral Vectors
1.2.3.4. Non-viral Vectors
1.2.3.5. Others
1.2.4. Cancer Gene Therapy Market By End-Use
1.2.4.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison By End-Use (2015-2026)
1.2.4.2. Global Cancer Gene Therapy Market Revenue Share By End-Use in 2017
1.2.4.3. Hospitals
1.2.4.4. Biopharma companies
1.2.4.5. Research Institutes
1.2.4.6. Others
1.2.5. Cancer Gene Therapy Market By Geography
1.2.5.1. Global Cancer Gene Therapy Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Cancer Gene Therapy Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cancer Gene Therapy Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Cancer Gene Therapy Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Cancer Gene Therapy Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Cancer Gene Therapy Major Manufacturers in 2017
CHAPTER 4. CANCER GENE THERAPY MARKET By TYPE
4.1. Global Cancer Gene Therapy Revenue By Type
4.2. Ex-vivo
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. In-vivo
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. CANCER GENE THERAPY MARKET BY PRODUCT
5.1. Global Cancer Gene Therapy Revenue By Product
5.2. Viral Vectors
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Non-viral Vectors
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. CANCER GENE THERAPY MARKET BY END-USE
6.1. Global Cancer Gene Therapy Revenue By End-Use
6.2. Hospitals
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Biopharma companies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Research Institutes
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA CANCER GENE THERAPY MARKET BY COUNTRY
7.1. North America Cancer Gene Therapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Cancer Gene Therapy Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE CANCER GENE THERAPY MARKET BY COUNTRY
8.1. Europe Cancer Gene Therapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC CANCER GENE THERAPY MARKET BY COUNTRY
9.1. Asia-Pacific Cancer Gene Therapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA CANCER GENE THERAPY MARKET BY COUNTRY
10.1. Latin America Cancer Gene Therapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST & Africa CANCER GENE THERAPY MARKET BY COUNTRY
11.1. Middle East & Africa Cancer Gene Therapy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & Africa Cancer Gene Therapy Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.5. Rest of Middle East & Africa
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 12. COMPANY PROFILE
12.1. Vigene Biosciences
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Sirion Biotech
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Bluebird Bio
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Cellectis
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Ziopharm
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Cobra
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Finvector
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sangamo Therapists Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Novartis AG
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Sarepta Therapeutics
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Caribou
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Others
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Product Portfolio
12.12.5. Key Developments
12.12.6. Strategies
CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope
The main function of cancer gene therapy is regeneration or replacement of mutated genes with healthy genes.
Factors such as rising prevalence of cancer, increase in geriatric population across the globe restrain the cancer gene therapy market growth.
Acumen Research and Consulting says that, the cancer gene therapy market value is anticipated to be worth around US$ 3.2 million in 2026.
The cancer gene therapy market is anticipated to grow over 29.7% CAGR during the forecast period 2019 to 2026.
North America held maximum share in 2018 for cancer gene therapy market.
Asia Pacific is projected to grow at a fast pace during forecast period in the cancer gene therapy market.
Vigene Biosciences, Sirion Biotech, bluebird bio, Cellectis, and Ziopharm, Cobra, Finvector, Sangamo Therapists Inc., Novartis AG, Sarepta Therapeutics are the top players operating in the cancer gene therapy market.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date